Research Office - College of Medicine

Forms

Internal Form GBR Proposal Budget Worksheet Budget Transfer RET Underwrite Underwrite-CS SF424 Template IACUC IRB Grant Tuition Payment Request

Funding Opportunities

Current Funding Opportunities Funding Opportunities Archives Community of Science Limited Submission Bridge Funding Selected Federal Funding Opportunities

Grant Resources

Grants.gov NIH NSF Indirect Cost Division of Sponsored Research Research Financial Management Useable Grant Text USF Research Facilities USF and USF Health Boilerplate

Research Resources

Research Directory Library PubMed Institute of Clinical & Translational Research Fisher Scientific-USF Partnership Pricing

Core Facilities

Flow Microscopy Behavior Proteomic & Genomics Small Animal Imaging Biostatistics COM Shared Equipment Moffitt Shared Resources Usable Grant Text

Research Policies

Bridge Funding Policy Statement Graduate Tuition Policy Salary on Grants/Contract Salary Enhancement Program (pending) Research Support Account

USF Compliance Offices

Comparative Medicine HIPAA Compliance IRB Office of Research Compliance Research Integrity Biosafety Diving Safety Program Radiation Safety Enviromental Health & Safety

My Profile

Jeffrey Krischer , PHD
Administrative Appointment: Division Chief
Primary Department: COLLEGE OF MEDICINE PEDIATRICS

Distinguished Prof & Director
COLLEGE OF MEDICINE PEDIATRICS

Distinguished Professor
COLLEGE OF MEDICINE NEUROLOGY

Contacts
Email:	jkrische@health.usf.edu
Phone:	(813) 396-9512
Office:	HLM, 201
Mailing address	3650 Spectrum Blvd Tampa, FL 33612
View My C.V.

Education

PHD, Applied Mathematics, Harvard University , Cambridge, United States - 1974.

Selected Publications

Richesson, RL.Krischer, J. Data standards in clinical research: gaps, overlaps, challenges and future directions. Journal of the American Medical Informatics Association : JAMIA. 14(6): 687-96, .

Andrews, JE.Richesson, RL.Krischer, J. Variation of SNOMED CT coding of clinical research concepts among coding experts. Journal of the American Medical Informatics Association : JAMIA. 14(4): 497-506, .

Richesson, RL.Andrews, JE.Krischer, JP. Use of SNOMED CT to represent clinical research data: a semantic characterization of data items on case report forms in vasculitis research. Journal of the American Medical Informatics Association : JAMIA. 13(5): 536-46, .

Roetzheim, RG.Christman, LK.Jacobsen, PB.Cantor, AB.Schroeder, J.Abdulla, R.Hunter, S.Chirikos, TN.Krischer, JP. A randomized controlled trial to increase cancer screening among attendees of community health centers. Annals of family medicine. 2(4): 294-300, .

Papaconstantinou, C.Krischer, JP. An automated patient registration and treatment randomization system. Journal of medical systems. 19(6): 445-56, 1995.

Cantor, AB.Krischer, JP.Cuthbertson, DD.Schatz, DA.Riley, WJ.Malone, J.Schwartz, S.Quattrin, T.Maclaren, NK. Age and family relationship accentuate the risk of insulin-dependent diabetes mellitus (IDDM) in relatives of patients with IDDM. The Journal of clinical endocrinology and metabolism. 80(12): 3739-43, 1995.

Roetzheim, RG.Pal, N.Tennant, C.Voti, L.Ayanian, JZ.Schwabe, A.Krischer, JP. Effects of health insurance and race on early detection of cancer. Journal of the National Cancer Institute. 91(16): 1409-15, 1999.

Roetzheim, RG.Pal, N.Gonzalez, EC.Ferrante, JM.Van Durme, DJ.Ayanian, JZ.Krischer, JP. The effects of physician supply on the early detection of colorectal cancer. The Journal of family practice. 48(11): 850-8, 1999.

Roetzheim, RG.Pal, N.Gonzalez, EC.Ferrante, JM.Van Durme, DJ.Krischer, JP. Effects of health insurance and race on colorectal cancer treatments and outcomes. American journal of public health. 90(11): 1746-54, 2000.

Roetzheim, RG.Pal, N.van Durme, DJ.Wathington, D.Ferrante, JM.Gonzalez, EC.Krischer, JP. Increasing supplies of dermatologists and family physicians are associated with earlier stage of melanoma detection. Journal of the American Academy of Dermatology. 43(2 Pt 1): 211-8, 2000.

Roetzheim, RG.Gonzalez, EC.Ferrante, JM.Pal, N.Van Durme, DJ.Krischer, JP. Effects of health insurance and race on breast carcinoma treatments and outcomes. Cancer. 89(11): 2202-13, 2000.

Chirikos, TN.Ruckdeschel, JC.Krischer, JP. Impact of clinical trials on the cost of cancer care. Medical care. 39(4): 373-83, 2001.

Krischer, JP.Cuthbertson, DD.Yu, L.Orban, T.Maclaren, N.Jackson, R.Winter, WE.Schatz, DA.Palmer, JP.Eisenbarth, GS. Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. The Journal of clinical endocrinology and metabolism. 88(1): 103-8, 2003.

Sutphen, R.Xu, Y.Wilbanks, GD.Fiorica, J.Grendys, EC.LaPolla, JP.Arango, H.Hoffman, MS.Martino, M.Wakeley, K.Griffin, D.Blanco, RW.Cantor, AB.Xiao, YJ.Krischer, JP. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 13(7): 1185-91, 2004.

Krischer, JP.Cuthbertson, DD.Greenbaum, C. Male sex increases the risk of autoimmunity but not type 1 diabetes. Diabetes care. 27(8): 1985-90, 2004.

Fink, E.Kokku, PK.Nikiforou, S.Hall, LO.Goldgof, DB.Krischer, JP. Selection of patients for clinical trials: an interactive web-based system. Artificial intelligence in medicine. 31(3): 241-54, 2004.

Krischer, J. The biostatistics of prediction. Autoimmunity. 37(4): 261-3, 2004.

Richesson, R.Young, K.Guillette, H.Tuttle, M.Abbondondolo, M.Krischer, J. Standard terminology on demand: facilitating distributed and real-time use of SNOMED CT during the clinical research process. AMIA ... Annual Symposium proceedings / AMIA Symposium. AMIA Symposium. (): 1076, 2006.

Richesson, RL.Young, K.Lloyd, J.Adams, T.Guillette, H.Malloy, J.Krischer, JP. An automated communication system in a Contact Registry for persons with rare diseases: tools for retaining potential clinical research participants. AMIA ... Annual Symposium proceedings / AMIA Symposium. AMIA Symposium. (): 1094, 2007.

Richesson, R.Syed, A.Guillette, H.Tuttle, MS.Krischer, J. A web-based SNOMED CT browser: distributed and real-time use of SNOMED CT during the clinical research process. Studies in health technology and informatics. 129(Pt 1): 631-5, 2007.

Xu, P.Cuthbertson, D.Greenbaum, C.Palmer, JP.Krischer, JP. Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes care. 30(9): 2314-20, 2007.

Krischer, MM.Xu, P.Meade, CD.Jacobsen, PB. Self-administered stress management training in patients undergoing radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 25(29): 4657-62, 2007.

Richesson, RL.Malloy, JF.Paulus, K.Cuthbertson, D.Krischer, JP. An automated standardized system for managing adverse events in clinical research networks. Drug safety : an international journal of medical toxicology and drug experience. 31(10): 807-22, 2008.

Kumar, NB.Besterman-Dahan, K.Kang, L.Pow-Sang, J.Xu, P.Allen, K.Riccardi, D.Krischer, JP. Results of a Randomized Clinical Trial of the Action of Several Doses of Lycopene in Localized Prostate Cancer: Administration Prior to Radical Prostatectomy. Clinical medicine. Urology [electronic resource]. 1(): 1-14, 2008.

Richesson, RL.Fung, KW.Krischer, JP. Heterogeneous but "standard" coding systems for adverse events: Issues in achieving interoperability between apples and oranges. Contemporary clinical trials. 29(5): 635-45, 2008.

Andrews, JE.Patrick, TB.Richesson, RL.Brown, H.Krischer, JP. Comparing heterogeneous SNOMED CT coding of clinical research concepts by examining normalized expressions. Journal of biomedical informatics. 41(6): 1062-9, 2008.

Couluris, M.Mayer, JL.Freyer, DR.Sandler, E.Xu, P.Krischer, JP. The effect of cyproheptadine hydrochloride (periactin) and megestrol acetate (megace) on weight in children with cancer/treatment-related cachexia. Journal of pediatric hematology/oncology. 30(11): 791-7, 2008.

Krischer, MM.Xu, P. Determinants of psychological functioning in patients undergoing radiotherapy: a descriptive study. Journal of psychosocial oncology. 26(4): 1-13, 2008.

Inoue, Y.Trapnell, BC.Tazawa, R.Arai, T.Takada, T.Hizawa, N.Kasahara, Y.Tatsumi, K.Hojo, M.Ichiwata, T.Tanaka, N.Yamaguchi, E.Eda, R.Oishi, K.Tsuchihashi, Y.Kaneko, C.Nukiwa, T.Sakatani, M.Krischer, JP.Nakata, K. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. American journal of respiratory and critical care medicine. 177(7): 752-62, 2008.

Moyers, S.Richesson, R.Krischer, J. Trans-atlantic data harmonization in the classification of medicines and dietary supplements: a challenge for epidemiologic study and clinical research. International journal of medical informatics. 77(1): 58-67, 2008.

Uchida, K.Nakata, K.Suzuki, T.Luisetti, M.Watanabe, M.Koch, DE.Stevens, CA.Beck, DC.Denson, LA.Carey, BC.Keicho, N.Krischer, JP.Yamada, Y.Trapnell, BC. Granulocyte/macrophage colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy individuals. Blood. (): , 2008.

Sosenko, JM.Palmer, JP.Rafkin-Mervis, L.Krischer, JP.Cuthbertson, D.Matheson, D.Skyler, JS. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes care. 31(11): 2188-92, 2008.

Orban, T.Sosenko, JM.Cuthbertson, D.Krischer, JP.Skyler, JS.Jackson, R.Yu, L.Palmer, JP.Schatz, D.Eisenbarth, G. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes care. 32(12): 2269-74, 2009.

Roesch, LF.Casella, G.Simell, O.Krischer, J.Wasserfall, CH.Schatz, D.Atkinson, MA.Neu, J.Triplett, EW. Influence of fecal sample storage on bacterial community diversity. The open microbiology journal. 3(): 40-6, 2009.

Sosenko, JM.Palmer, JP.Rafkin-Mervis, L.Krischer, JP.Cuthbertson, D.Mahon, J.Greenbaum, CJ.Cowie, CC.Skyler, JS. Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1. Diabetes care. 32(9): 1603-7, 2009.

Richesson, RL.Lee, HS.Cuthbertson, D.Lloyd, J.Young, K.Krischer, JP. An automated communication system in a contact registry for persons with rare diseases: scalable tools for identifying and recruiting clinical research participants. Contemporary clinical trials. 30(1): 55-62, 2009.

Sosenko, JM.Palmer, JP.Rafkin, LE.Krischer, JP.Cuthbertson, D.Greenbaum, CJ.Eisenbarth, G.Skyler, JS. Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes care. 33(3): 620-5, 2010.

Tazawa, R.Trapnell, BC.Inoue, Y.Arai, T.Takada, T.Nasuhara, Y.Hizawa, N.Kasahara, Y.Tatsumi, K.Hojo, M.Ishii, H.Yokoba, M.Tanaka, N.Yamaguchi, E.Eda, R.Tsuchihashi, Y.Morimoto, K.Akira, M.Terada, M.Otsuka, J.Ebina, M.Kaneko, C.Nukiwa, T.Krischer, JP.Akazawa, K.Nakata, K. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. American journal of respiratory and critical care medicine. 181(12): 1345-54, 2010.

Seminara, J.Tuchman, M.Krivitzky, L.Krischer, J.Lee, HS.Lemons, C.Baumgartner, M.Cederbaum, S.Diaz, GA.Feigenbaum, A.Gallagher, RC.Harding, CO.Kerr, DS.Lanpher, B.Lee, B.Lichter-Konecki, U.McCandless, SE.Merritt, JL.Oster-Granite, ML.Seashore, MR.Stricker, T.Summar, M.Waisbren, S.Yudkoff, M.Batshaw, ML. Establishing a consortium for the study of rare diseases: The Urea Cycle Disorders Consortium. Molecular genetics and metabolism. 100 Suppl 1(): S97-105, 2010.

Levis, S.Strickman-Stein, N.Doerge, DR.Krischer, J. Design and baseline characteristics of the soy phytoestrogens as replacement estrogen (SPARE) study--a clinical trial of the effects of soy isoflavones in menopausal women. Contemporary clinical trials. 31(4): 293-302, 2010.

Bonifacio, E.Yu, L.Williams, AK.Eisenbarth, GS.Bingley, PJ.Marcovina, SM.Adler, K.Ziegler, AG.Mueller, PW.Schatz, DA.Krischer, JP.Steffes, MW.Akolkar, B. Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. The Journal of clinical endocrinology and metabolism. 95(7): 3360-7, 2010.

Sorkio, S.Cuthbertson, D.Bärlund, S.Reunanen, A.Nucci, AM.Berseth, CL.Koski, K.Ormisson, A.Savilahti, E.Uusitalo, U.Ludvigsson, J.Becker, DJ.Dupré, J.Krischer, JP.Knip, M.Akerblom, HK.Virtanen, SM. Breastfeeding patterns of mothers with type 1 diabetes: results from an infant feeding trial. Diabetes/metabolism research and reviews. 26(3): 206-11, 2010.

Sosenko, JM.Mahon, J.Rafkin, L.Lachin, JM.Krause-Steinrauf, H.Krischer, JP.Cuthbertson, D.Palmer, JP.Thompson, C.Greenbaum, CJ.Skyler, JS. A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. Pediatric diabetes. (): , 2010.

Richesson, RL.Smith, SB.Malloy, J.Krischer, JP. Achieving standardized medication data in clinical research studies: two approaches and applications for implementing RxNorm. Journal of medical systems. 34(4): 651-7, 2010.

Xu, P.Wu, Y.Zhu, Y.Dagne, G.Johnson, G.Cuthbertson, D.Krischer, JP.Sosenko, JM.Skyler, JS. Prognostic performance of metabolic indexes in predicting onset of type 1 diabetes. Diabetes care. 33(12): 2508-13, 2010.

Lee, HS.Paik, MC.Rundek, T.Sacco, RL.Dong, C.Krischer, JP. Heritability Estimation using Regression Models for Correlation. Journal of biometrics & biostatistics. 2(119): , 2011.

Vehik, K.Beam, CA.Mahon, JL.Schatz, DA.Haller, MJ.Sosenko, JM.Skyler, JS.Krischer, JP. Development of autoantibodies in the TrialNet Natural History Study. Diabetes care. 34(9): 1897-901, 2011.

Vehik, K.Cuthbertson, D.Ruhlig, H.Schatz, DA.Peakman, M.Krischer, JP. Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial. Diabetes care. 34(7): 1585-90, 2011.

Vehik, K.Haller, MJ.Beam, CA.Schatz, DA.Wherrett, DK.Sosenko, JM.Krischer, JP. Islet autoantibody seroconversion in the DPT-1 study: justification for repeat screening throughout childhood. Diabetes care. 34(2): 358-62, 2011.

Grants

ANTI-CD3 (TEPLIZUMAB) FOR PREVENTION OF DIABETES IN RELATIVES AT RISK FOR TYPE 1 DIABETES MELLITUS - CLINICAL MONITORING & TRAVEL AGREEMENT ($1,397,725.00, 09/01/2010-08/31/2017)

DATA COORDINATING CENTER FOR THE CONSORTIUM FOR IDENTIFICATION OF ENVIRONMENTAL DETERMINANTS OF DIABETES IN THE YOUNG (TEDDY) STUDY (UC4) ($11,245,989.00, 09/29/2011-06/30/2016)

DATA COORDINATING CENTER FOR THE CONSORTIUM FOR IDENTIFICATION OF ENVIRONMENTAL DETERMINANTS OF DIABETES IN THE YOUNG (TEDDY) STUDY (UC4) ($11,220,650.00, 09/29/2011-06/30/2016)

TRIAL TO REDUCE IDDM IN THE GENETICALLY AT RISK (TRIGR) DATA MANAGEMENT UNIT ($745,855.00, 07/01/2011-06/30/2016)

TRIAL TO REDUCE IDDM IN THE GENETICALLY AT RISK (TRIGR) DATA MANAGEMENT UNIT ($747,986.00, 07/01/2011-06/30/2016)

RESEARCH SERVICES AGREEMENT ACZ88512201 ($1,735,267.00, 10/21/2010-10/01/2015)

NIDDK TYPE 1 DIABETES TRIALNET DATA COORDINATING CENTER ($8,388,706.00, 07/22/2008-07/21/2015)

NIDDK TYPE 1 DIABETES TRIALNET DATA COORDINATING CENTER ($22,348,255.00, 07/22/2008-07/21/2015)

NIDDK TYPE 1 DIABETES TRIALNET DATA COORDINATING CENTER ($61,545,981.00, 07/22/2008-07/21/2015)

NIDDK TYPE 1 DIABETES TRIALNET DATA COORDINATING CENTER (($40,004,888.00), 07/22/2008-07/21/2015)

NIDDK TYPE 1 DIABETES TRIALNET DATA COORDINATING CENTER ($2,671,172.00, 07/22/2008-07/21/2015)

NIDDK TYPE 1 DIABETES TRIALNET DATA COORDINATING CENTER ($19,435,405.00, 07/22/2008-07/21/2015)

NIDDK TYPE 1 DIABETES TRIALNET DATA COORDINATING CENTER ($22,192,535.00, 07/22/2008-07/21/2015)

NIDDK TYPE 1 DIABETES TRIALNET DATA COORDINATING CENTER ($3,373,460.00, 07/22/2008-07/21/2015)

NIDDK TYPE 1 DIABETES TRIALNET DATA COORDINATING CENTER ($22,978,840.00, 07/22/2008-07/21/2015)

SUNCOAST CCOP RESEARCH BASE AT THE UNIVERSITY OF SOUTH FLORIDA ($1,830,654.00, 06/01/2010-05/31/2015)

SUNCOAST CCOP RESEARCH BASE AT THE UNIVERSITY OF SOUTH FLORIDA ($1,497,393.00, 06/01/2010-05/31/2015)

RARE DISEASES DATA MANAGEMENT AND COORDINATING CENTER ($500,000.00, 09/01/2010-07/31/2014)

RARE DISEASES DATA MANAGEMENT AND COORDINATING CENTER ($3,075,481.00, 09/01/2010-07/31/2014)

RARE DISEASES DATA MANAGEMENT AND COORDINATING CENTER ($1,200,000.00, 09/01/2010-07/31/2014)

RARE DISEASES DATA MANAGEMENT AND COORDINATING CENTER ($500,000.00, 09/01/2010-07/31/2014)

RARE DISEASES DATA MANAGEMENT AND COORDINATING CENTER ($3,000,000.00, 09/01/2010-07/31/2014)

RARE DISEASES DATA MANAGEMENT AND COORDINATING CENTER ($500,000.00, 09/01/2010-07/31/2014)

RARE DISEASES DATA MANAGEMENT AND COORDINATING CENTER ($959,195.00, 09/01/2010-07/31/2014)

FOLLOW-UP OF CHILDREN DIAGNOSED WITH DIABETES ($1,162,163.00, 07/01/2011-06/30/2014)

FOLLOW-UP OF CHILDREN DIAGNOSED WITH DIABETES ($1,125,991.00, 07/01/2011-06/30/2014)

LAM CLINICS REGISTRY DATABASE ($75,000.00, 09/15/2010-10/14/2013)

LAM CLINICS REGISTRY DATABASE ($100,000.00, 09/15/2010-10/14/2013)

OI DATA COLLECTION CENTER FOR LINKED CLINICAL RESEARCH CENTERS ($25,000.00, 07/01/2008-06/30/2013)

OI DATA COLLECTION CENTER FOR LINKED CLINICAL RESEARCH CENTERS ($50,000.00, 07/01/2008-06/30/2013)

PHASE I STUDY OF LENALIDOMIDE IN COMBINATION WITH 5-AZACYTIDINE IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROME (MDS) ($36,750.00, 04/30/2010-04/29/2013)

CONCURRENT PILOT STUDIES IN GIANT CELL ARTERITIS (GCA) AND TAKAYASU'S ARTERITIS (TAK) TO EXAMINE THE SAFETY, EFFICACY, AND IMMUNOLOGIC EFFECTS OF ABATACEPT (CTLA4-IG) IN LARGE VESSEL VASCULITIS ($114,543.00, 08/15/2007-04/14/2013)

REPRODUCTIVE HEALTH IN MEN AND WOMEN WITH VASCULITIS ($25,000.00, 12/01/2011-07/31/2012)

GENETIC DISORDER OF MUCOCILARY CLEARANCE ($60,290.00, 09/01/2009-07/31/2012)

GENETIC DISORDER OF MUCOCILARY CLEARANCE ($61,520.00, 09/01/2009-07/31/2012)

RARE DISEASE RESEARCH ($75,000.00, 08/01/2009-07/31/2012)

RARE DISEASE CRC FOR NEW THERAPIES AND NEW DIAGNOSTICS ($24,000.00, 08/01/2009-07/31/2012)

RARE DISEASE CRC FOR NEW THERAPIES AND NEW DIAGNOSTICS ($38,220.00, 08/01/2009-07/31/2012)

OI DATA COLLECTION CENTER FOR LINKED CLINICAL RESEARCH CENTERS ($100,000.00, 07/01/2008-06/30/2012)

NF CONSORTIUM OPERATION CENTER PROTOCOL 102 MTOR ($7,325.00, 11/01/2007-04/30/2012)

NERVOUS SYSTEM CHANNELOPATHIES: PATHOGENESIS AND TREATMENT ($147,000.00, 09/01/2010-02/29/2012)

VASCULITIS CLINICAL RESEARCH CONSORTIUM 2 ($34,204.00, 09/01/2011-12/31/2011)

NF CONSORTIUM OPERATION CENTER PROTOCOL 102 MTOR ($14,700.00, 11/01/2007-10/31/2011)

TRIAL TO REDUCE IDDM IN THE GENETICALLY AT RISK (TRIGR) DATA MANAGEMENT UNIT ($140,584.00, 09/30/2009-09/29/2011)

THE ENVIRONMENTAL DETERMINANTS OF DIABETES IN THE YOUTH STUDY (TEDDY) DATA COORDINATING CENTER ($17,266,132.00, 09/15/2007-09/14/2011)

THE ENVIRONMENTAL DETERMINANTS OF DIABETES IN THE YOUTH STUDY (TEDDY) DATA COORDINATING CENTER ($5,000,000.00, 09/15/2007-09/14/2011)

INHERITED NEUROPATHIES CONSORTIUM (RDCRC) ($95,550.00, 01/01/2011-08/31/2011)

NERVOUS SYSTEM CHANNELOPATHIES: PATHOGENESIS AND TREATMENT ($147,000.00, 09/30/2009-08/31/2011)

IDENTIFICATION AND VALIDATION OF BIOMARKERS FOR VASCULITIS ($59,765.00, 09/30/2009-08/31/2011)

IDENTIFICATION AND VALIDATION OF BIOMARKERS FOR VASCULITIS ($11,604.00, 09/30/2009-08/31/2011)

VASULITIS CLINICAL RESEARCH CONSORTIUM ($79,511.00, 09/01/2009-08/31/2011)

RARE DISEASE RESEARCH ($75,000.00, 08/01/2009-07/31/2011)

TRIAL TO REDUCE IDDM IN THE GENETICALLY AT RISK (TRIGR) DATA MANAGEMENT UNIT ($549,500.00, 07/01/2010-06/30/2011)

TRIAL TO REDUCE IDDM IN THE GENETICALLY AT RISK (TRIGR) DATA MANAGEMENT UNIT ($558,942.00, 07/01/2010-06/30/2011)

TRIAL TO REDUCE IDDM IN THE GENETICALLY AT RISK (TRIGR) DATA MANAGEMENT UNIT ($510,682.00, 07/01/2006-06/30/2011)

CONFERENCE ON CLINICAL RESEARCH FOR RARE DISEASE ($9,980.00, 04/01/2010-03/31/2011)

PROMIS NETWORK CENTER (SUBCONTRACT 622.02833) ($35,000.00, 12/20/2010-01/31/2011)

THE LAM FOUNDATION PROJECT - DMCC FOR THE MILES TRIAL ($112,000.00, 08/08/2009-12/31/2010)

ANTI-IL-1 TREATMENT IN NEW ONSET TYPE 1 DIABETES: STATISTICAL COORDINATION ($166,260.00, 12/01/2007-11/30/2010)

ANTI-IL-1 TREATMENT IN NEW-ONSET TYPE 1 DIABETES: STATISTICAL COORDINATION ($161,417.00, 12/01/2007-11/30/2010)

ANTI-IL-1 TREATMENT IN NEW-ONSET TYPE 1 DIABETES: STATISTICAL COORDINATION ($195,895.00, 12/01/2007-11/30/2010)

NF CONSORTIUM OPERATION CENTER PROTOCOL 102 MTOR ($14,700.00, 11/01/2007-10/31/2010)

THE ENVIRONMENTAL DETERMINANTS OF DIABETES IN THE YOUTH STUDY (TEDDY) DATA COORDINATING CENTER ($10,527,140.00, 09/15/2007-09/14/2010)

THE ENVIRONMENTAL DETERMINANTS OF DIABETES IN THE YOUTH STUDY (TEDDY) DATA COORDINATING CENTER ($3,308,144.00, 09/15/2007-09/14/2010)

THE ENVIRONMENTAL DETERMINANTS OF DIABETES IN THE YOUTH STUDY (TEDDY) DATA COORDINATING CENTER ($22,744,773.00, 09/15/2007-09/14/2010)

THE ENVIRONMENTAL DETERMINANTS OF DIABETES IN THE YOUTH STUDY (TEDDY) DATA COORDINATING CENTER ($20,178,412.00, 09/15/2007-09/14/2010)

NERVOUS SYSTEM CHANNELOPATHIES: PATHOGENESIS AND TREATMENT ($147,000.00, 09/30/2009-08/31/2010)

VASULITIS CLINICAL RESEARCH CONSORTIUM ($79,358.00, 09/01/2009-08/31/2010)

DATA MANAGEMENT AND COORDINATING CENTER (DMCC) - RARE DISEASES ($595,000.00, 08/01/2009-08/31/2010)

DATA MANAGEMENT AND COORDINATING CENTER (DMCC) - RARE DISEASES ($2,250,000.00, 08/01/2009-08/31/2010)

CONCURRENT PILOT STUDIES IN GIANT CELL ARTERIES (GCA) AND TAKAYASU'S ARTERITIES (TAK) TO EXAMINE THE SAFETY, EFFICACY, AND IMMUNOLOGIC EFFECTS OF ABATACEPT (CTLA4-IG) IN LARGE VESSEL VASCULITIS ($148,104.00, 08/15/2007-08/14/2010)

GENETIC DISORDER OF MUCOCILARY CLEARANCE ($61,520.00, 09/01/2009-07/31/2010)

RARE DISEASE RESEARCH ($75,000.00, 08/01/2009-07/31/2010)

TRIAL TO REDUCE IDDM IN THE GENETICALLY AT RISK( (TIGR) DATA MANAGEMENT UNIT ($540,912.00, 07/01/2009-06/30/2010)

H LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE ($1,357,083.00, 06/01/2009-05/31/2010)

H LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE ($910,062.00, 06/01/2000-05/31/2010)

TYPE 1 DIABETES TRIALNET: COORDINATING CENTER ($125,000.00, 07/01/2008-04/30/2010)

TYPE 1 DIABETES TRIALNET: COORDINATING CENTER (($15,000.00), 07/01/2008-04/30/2010)

TYPE 1 DIABETES TRIALNET: COORDINATING CENTER ($30,000.00, 07/01/2008-04/30/2010)

WEB-BASED TELEGENETICS PROJECT ($13,800.00, 01/01/2009-12/31/2009)

MULTI-CENTER, MULTI-NATIONAL, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF AZITHROMYCIN IN SUBJECTS WITH CYSTIC FIBROSIS 6-18 YEARS OLD, CULTURE-NEGATIVE FOR PSEUDOMONASAERUGINOSA ($278,441.00, 09/17/2007-12/31/2009)

NF CONSORTIUM OPERATION CENTER PROTOCOL 102 MTOR ($14,700.00, 11/01/2007-10/31/2009)

HYPERION - CONSULTATION AND DATA ANALYSIS ($7,651.00, 10/10/2008-10/09/2009)

TYPE 1 DIABETES TRIALNET: COORDINATING CENTER ($944,190.00, 07/01/2008-09/30/2009)

TYPE 1 DIABETES TRIALNET: COORDINATING CENTER ($3,684,736.00, 07/01/2008-09/30/2009)

THE DATA AND TECHNOLOGY COORDINATING CENTER FOR MEXILETINE STUDY ($147,000.00, 08/01/2008-07/31/2009)

RARE DISEASES DATA AND TECHNOLOGY COORDINATING CENTER ($400,000.00, 08/01/2007-07/31/2009)

RARE DISEASES DATA AND TECHNOLOGY COORDINATING CENTER ($966,226.00, 08/01/2007-07/31/2009)

RARE DISEASES DATA AND TECHNOLOGY COORDINATING CENTER ($1,828,136.00, 08/01/2007-07/31/2009)

TRIAL TO REDUCE IDDM IN THE GENETICALLY AT RISK (TRIGR) DATA MANAGEMENT UNIT ($555,175.00, 07/01/2008-06/30/2009)

OI DATA COLLECTION CENTER FOR LINKED CLINICAL RESEARCH CENTERS ($100,000.00, 07/01/2008-06/30/2009)

H LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE ($468,403.00, 06/01/2008-05/31/2009)

H LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE ($317,475.00, 06/01/2008-05/31/2009)

TARGETED DRUG THERAPY FOR LGL LEUKEMIA (MOFFITT) ($27,620.00, 08/15/2005-05/31/2009)

NF CONSORTIUM OPERATION CENTER PROTOCOL 102 MTOR ($36,625.00, 11/01/2007-10/30/2008)

TARGETED DRUG THERAPY FOR LGL LEUKEMIA ($27,620.00, 08/15/2005-08/31/2008)

RARE DISEASES DATA AND TECHNOLOGY COORDINATING CENTER ($3,000,000.00, 08/01/2004-07/31/2008)

TYPE 1 DIABETES TRIAL NET ($49,735.00, 07/01/2007-06/30/2008)

TRIAL TO REDUCE IDDM IN THE GENETICALLY AT RISK (TRIGR) DATA MANAGEMENT UNIT ($110,000.00, 07/01/2007-06/30/2008)

TRIAL TO REDUCE IDDM IN THE GENETICALLY AT RISK (TRIGR) DATA MANAGEMENT UNIT ($427,598.00, 07/01/2007-06/30/2008)

TYPE 1 DIABETES TRIAL NET ($680,062.00, 07/01/2007-06/30/2008)

CYSTIC FIBROSIS TREATMENT DEVELOPMENT NETWORK ($279,792.00, 09/01/2005-09/16/2007)

DATA COORDINATING CENTER (TEDDY) ($12,044,731.00, 09/01/2006-08/31/2007)

DATA COORDINATING CENTER (TEDDY) ($20,127,297.00, 09/01/2005-08/31/2007)

TEDDY DATA COORDINATING CENTER ($11,365,000.00, 09/01/2004-08/31/2007)

TEDDY DATA COORDINATING CENTER ($3,098,992.00, 09/01/2004-08/31/2007)

RARE DISEASES DATA & TECHNOLOGY COORDINATING CENTER ($3,146,231.00, 08/01/2006-07/31/2007)

TYPE 1 DIABETES TRIAL NET ($50,529.00, 07/01/2006-06/30/2007)

CYSTIC FIBROSIS TREATMENT DEVELOPMENT NETWORK ($271,541.00, 09/01/2005-06/30/2007)

H LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE ($978,561.00, 06/01/2006-05/31/2007)

TARGETED DRUG THERAPY FOR LGL LEUKEMIA ($27,780.00, 08/15/2005-05/31/2007)

TARGETED DRUG THERAPY FOR LGL LEUKEMIA ($27,620.00, 08/15/2005-05/31/2007)

FLORIDA NEUROFIBROMATOSIS RESEARCH NETWORK ($32,360.00, 01/01/2005-12/31/2006)

FLORIDA NEUROFIBROMATOSIS RESEARCH NETWORK ($37,783.00, 01/01/2005-12/31/2006)

ADVANCED CANCER DETECTION CENTER II ($928,025.00, 10/01/2001-10/31/2006)

ADVANCED CANCER DETECTION CENTER ($962,654.00, 10/01/2001-10/31/2006)

ADVANCED CANCER DETECTION CENTER ($1,081,613.00, 10/01/2001-10/31/2006)

ADVANCED CANCER DETECTION CENTER ($2,139,100.00, 10/01/2001-10/31/2006)

VASCULITIS OUTCOME MEASURES: DEVELOPMENT AND VALIDATION ($25,956.00, 09/27/2004-09/30/2006)

RARE DISEASES DATA & TECHNOLOGY COORDINATING CENTER ($3,104,899.00, 08/01/2005-07/31/2006)

NUTRITIONAL PRIMARY PREVENTION OF TYPE 1 DIABETES ($60,000.00, 07/01/2004-06/30/2006)

NUTRITIONAL PRIMARY PREVENTION OF TYPE 1 DIABETES ($159,880.00, 07/01/2004-06/30/2006)

NUTRITIONAL PRIMARY PREVENTION OF TYPE 1 DIABETES ($200,000.00, 07/01/2004-06/30/2006)

TYPE 1 DIABETES TRIAL NET ($46,874.00, 07/01/2004-06/30/2006)

SUPPORT OF THE TELEMEDICINE PROJECT ($1,773.00, 07/01/2001-06/30/2006)

H. LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE ($986,002.00, 06/01/2005-05/31/2006)

CYSTIC FIBROSIS TREATMENT DEVELOPMENT NETWORK ($145,986.00, 09/01/2005-03/31/2006)

DTP-1 TWIN STUDY ($12,800.00, 01/19/2005-12/31/2005)

ADVANCED CANCER DETECTION CENTER II ($1,117,610.00, 10/01/2001-09/30/2005)

DATA COORDINATING CENTER (TEDDY) ($2,011,031.00, 09/01/2004-08/31/2005)

DATA COORDINATING CENTER (TEDDY) ($679.00, 09/01/2004-08/31/2005)

VASCULITIS OUTCOME MEASURES: DEVELOPMENT AND VALIDATION ($25,200.00, 09/27/2004-06/30/2005)

TYPE 1 DIABETES TRIAL NET ($37,711.00, 07/01/2004-06/30/2005)

NUTRITIONAL PRIMARY PREVENTION OF TYPE 1 DIABETES ($100,000.00, 07/01/2004-06/30/2005)

NUTRITIONAL PRIMARY PREVENTION OF TYPE 1 DIABETES ($200,000.00, 07/01/2004-06/30/2005)

TYPE 1 DIABETES TRIAL NET ($19,125.00, 07/01/2004-06/30/2005)

NUTRITIONAL PRIMARY PREVENTION OF TYPE 1 DIABETES ($300,000.00, 07/01/2004-06/30/2005)

H. LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE ($898,139.00, 06/01/2004-05/31/2005)

ANTIBODIES TO RECOMBINANT AUTOANTIGENS-PREDICT ($29,500.00, 06/01/2004-05/31/2005)

TYPE 1 DIABETES TRIAL NET ($196,086.00, 09/01/2003-08/31/2004)

TYPE 1 DIABETES TRIAL NET ($17,863.00, 09/01/2003-08/31/2004)

NUTRITION PRIMARY PREVENTION OF TYPE I DIABETES ($400,000.00, 07/01/2003-06/30/2004)

MOFFITT\DEPARTMENT OF PEDIATRICS SUPPORT ($75,259.00, 10/18/1993-06/30/2004)

MOFFITT\DEPARTMENT OF PEDIATRICS SUPPORT ($32,228.00, 10/18/1993-06/30/2004)

MOFFITT\DEPARTMENT OF PEDIATRICS SUPPORT ($34,341.00, 10/18/1993-06/30/2004)

H. LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE ($537,759.00, 06/01/2002-05/31/2004)

TRIAL NET DATA MANAGEMENT UNIT (TYPE I DIABETES TRIAL NET) ($616,270.00, 09/01/2002-08/31/2003)

NUTRITIONAL PRIMARY PREVENTION OF TYPE I DIABETES ($8,000.00, 07/01/2002-06/30/2003)

NUTRITIONAL PRIMARY PREVENTION OF TYPE I DIABETES ($392,000.00, 07/01/2002-06/30/2003)

TRIGR: TRIAL TO REDUCE IDDM IN THE GENETICALLY AT RISK ($236,904.00, 01/01/2002-06/30/2003)

TRIGR: TRIAL TO REDUCE IDDM IN THE GENETICALLY AT RISK ($139,121.00, 01/01/2002-06/30/2003)

DQB*0602 RELATIVES: MECHANISMS FOR DIABETES PROTECTION ($70,623.00, 06/01/2001-05/31/2003)

H. LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE ($588,420.00, 06/01/2000-05/31/2003)

H. LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE ($103,011.00, 06/01/2000-05/31/2003)

H. LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE ($25,000.00, 06/01/2000-05/31/2003)

H. LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE ($394,188.00, 06/01/2000-05/31/2003)

H. LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE ($575,473.00, 06/01/2000-05/31/2003)

TRIAL NET DATA MANAGEMENT UNIT (TYPE I DIABETES TRIAL NET) ($823,600.00, 09/01/2001-08/31/2002)

ANTIBODIES TO RECOMBINANT AUTOANTIGENS: PREDICTION/IMMUNOGENETICS ($24,583.00, 05/01/2001-07/31/2002)

ANTIBODIES TO RECOMBINANT AUTOANTIGENS: PREDICTION/IMMUNOGENETICS ($26,550.00, 05/01/2001-07/31/2002)

PREVENTION OF TYPE I DIABETES MELLITUS ($33,773.00, 09/01/2000-12/31/2001)

PREVENTION OF TYPE I DIABETES MELLITUS ($187,920.00, 09/01/2000-12/31/2001)

ADVANCED CANCER DETECTION CENTER ($1,873,571.00, 10/01/1998-10/31/2001)

PREVENTION OF TYPE I DIABETES MELLITUS ($882,190.00, 09/01/2000-08/31/2001)

ANTIBODIES TO RECOMBINANT AUTOANTIGENS: PREDICTION/IMMUNOGENETICS ($30,715.00, 05/01/1996-04/30/2001)

PREVENTION OF TYPE I DIABETES MELLITUS ($117,909.00, 09/01/1999-08/31/2000)

Profile last modified on 01/22/2013

SIGNATURE PROGRAMS

Allergy, Immunology and Infectious Diseases Cancer Biology Cardiovascular Research Neuroscience Research

New Collaborative

USF Neuroscience Collaborative – NSC

Emerging Areas
of Interest

Biomedical Engineering Nanomedicine Neuromusculoskeletal Disorders(NEW) Pharmacogenomics Regenerative Medicine Sports Medicine Women's Health

COM Approved
Centers/Institutes

Archie A. & Mary-Louise Silver Child Development Center Byrd Alzheimer’s Institute Cardiac Hormone Center Center for Aging & Brain Repair Center for Hospice, Palliative Care & End of Life Studies Diabetes Center Florida Infectious Disease Center Institute for Research In Psychiatry and Neurosciences Joy McCann Culverhouse Center for Swallowing Disorders Nanomedicine Research Center Pediatrics Epidemiology Center Suncoast Alzheimer's Clinic USF Parkinson's Disease and Movement Disorders Center, NPF Center of Excellence